Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

被引：21

作者：

Kelley, Michael J. ^{[1
,2
,3
]}

Jha, Gautam ^{[4
]}

Shoemaker, Debra ^{[2
]}

Herndon, James E., II ^{[2
]}

Gu, Lin ^{[2
]}

Barry, William T. ^{[2
,5
]}

Crawford, Jeffrey ^{[1
,2
]}

Ready, Neal ^{[1
,2
]}

机构：

[1] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA

[2] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA

[3] Durham Vet Affairs Med Ctr, Med Serv, Durham, NC USA

[4] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA

[5] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA

来源：

CANCER INVESTIGATION | 2017年 / 35卷 / 01期

关键词：

Non-small cell lung cancer; Src; gene expression; ERLOTINIB; TRIAL;

D O I：

10.1080/07357907.2016.1253710

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients who underwent pre-treatment biopsy for RNA biomarker analysis, 25 were treated with dasatinib 70 mg twice daily. There were no responses. Five patients discontinued treatment due to toxicity. Three patients hadminor biopsy-related pneumothoraces. Given the lack of responses, no biomarkers were analyzed. Dasatinib 70 mg twice daily does not have activity nor is it well tolerated in unselected patients with advanced stage, previously treated NSCLC.

引用

页码：32 / 35

页数：4

共 11 条

[1] Oncogenic pathway signatures in human cancers as a guide to targeted therapies [J].

Bild, AH ;

Yao, G ;

Chang, JT ;

Wang, QL ;

Potti, A ;

Chasse, D ;

Joshi, MB ;

Harpole, D ;

Lancaster, JM ;

Berchuck, A ;

Olson, JA ;

Marks, JR ;

Dressman, HK ;

West, M ;

Nevins, JR .

NATURE, 2006, 439 (7074) :353-357

[2] Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung [J].

Brunner, Andrew M. ;

Costa, Daniel B. ;

Heist, Rebecca S. ;

Garcia, Elizabeth ;

Lindeman, Neal I. ;

Sholl, Lynette M. ;

Oxnard, Geoffrey R. ;

Johnson, Bruce E. ;

Hammerman, Peter S. .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (11) :1434-1437

[3] Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non-Small-Cell Lung Cancer [J].

Haura, Eric B. ;

Tanvetyanon, Tawee ;

Chiappori, Alberto ;

Williams, Charles ;

Simon, George ;

Antonia, Scott ;

Gray, Jhanelle ;

Litschauer, Sharon ;

Tetteh, Leticia ;

Neuger, Anthony ;

Song, Lanxi ;

Rawal, Bhupendra ;

Schell, Michael J. ;

Bepler, Gerold .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) :1387-1394

[4]

Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.21492, 10.3322/caac.20107]

[5]

Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21254, 10.3322/caac.21332, 10.3322/caac.21551, 10.3322/caac.20073, 10.3322/caac.21387, 10.3322/caac.21654, 10.3322/caac.21601]

[6] Phase II Study of Dasatinib in Patients With Advanced Non-Small-Cell Lung Cancer [J].

Johnson, Faye M. ;

Bekele, B. Nebiyou ;

Feng, Lei ;

Wistuba, Ignacio ;

Tang, Xi Ming ;

Tran, Hai T. ;

Erasmus, Jeremy J. ;

Hwang, Li-Ling ;

Takebe, Naoko ;

Blumenschein, George R. ;

Lippman, Scott M. ;

Stewart, David J. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) :4609-4615

[7] Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib [J].

Johnson, Melissa L. ;

Riely, Greg J. ;

Rizvi, Naiyer A. ;

Azzoli, Christopher G. ;

Kris, Mark G. ;

Sima, Camelia S. ;

Ginsberg, Michelle S. ;

Pao, William ;

Miller, Vincent A. .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) :1128-1131

[8] A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602) [J].

Miller, Antonius A. ;

Pang, Herbert ;

Hodgson, Lydia ;

Ramnath, Nithya ;

Otterson, Gregory A. ;

Kelley, Michael J. ;

Kratzke, Robert A. ;

Vokes, Everett E. .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (03) :380-384

[9] Development of PI3K inhibitors: lessons learned from early clinical trials [J].

Rodon, Jordi ;

Dienstmann, Rodrigo ;

Serra, Violeta ;

Tabemero, Josep .

NATURE REVIEWS CLINICAL ONCOLOGY, 2013, 10 (03) :143-153

[10]

Shahbazian D, 2012, ADV PHARMACOL, V65, P1, DOI 10.1016/B978-0-12-397927-8.00001-4

← 1 2 →